Brought to you by 
Biogen Idec, Vernalis ally in Parkinson's disease; terminated
27 Apr 2021
Executive Summary
Drug development company Vernalis PLC (focuses on neuroscience and oncology) licensed Biogen Idec (therapeutics for disorders in oncology, neurology, dermatology, and rheumatology) exclusive worldwide rights to develop and commercialize its lead compound V2006 (formerly VR 2006), an adenosine A2A receptor antagonist in Phase I for Parkinson's disease (PD).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Equity
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Biogen Idec, Vernalis ally in Parkinson's disease; terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice